Johnson & Johnson Presents New Depression Data at 2026 ACNP Meeting
- 11 abstracts on neuropsychiatry will be presented at the 64th ACNP Annual Meeting.
- Key presentations include Phase 3 trials on CAPLYTA\u00ae and seltorexant.
- SPRAVATO\u00ae nasal spray effects on TRD anhedonia are explored.
- Research includes AI platforms and new therapeutic mechanisms for depression.
Event Overview
Johnson & Johnson will present 11 abstracts at the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Nassau, Bahamas, from January 12-15, 2026. The presentations will cover new data on their neuropsychiatry portfolio, focusing on major depressive disorder (MDD) and treatment-resistant depression (TRD).
Key Presentations
Significant presentations include a new analysis of Phase 3 clinical trials evaluating the efficacy of CAPLYTA® (lumateperone) combined with antidepressants for MDD symptom remission. Additionally, metabolic analyses of Phase 3 data will assess the tolerability of seltorexant, an investigational therapy, compared to quetiapine XR in MDD patients with insomnia symptoms.
Research Findings
Post-hoc analyses from two Phase 3 studies, TRANSFORM-2 and SUSTAIN-2, will explore the effects of SPRAVATO® (esketamine) nasal spray on anhedonia in TRD patients. The research aims to provide insights into the treatment's impact on this specific symptom.
Innovative Approaches
Preclinical and translational research will be showcased, highlighting novel AI platforms for precision medicine and investigations into the biology associated with neuropsychiatric diseases. Early-stage work on new therapeutic mechanisms for depression will also be presented, reflecting ongoing efforts to advance treatment options.
Source: J&J